World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
92
Citations
31341
World Ranking
11298
National Ranking
5798

Mario E. Lacouture publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Mario E. Lacouture sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 510 publications — 60th percentile

60% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Mario E. Lacouture D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Mario E. Lacouture sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 92 D-Index — 45th percentile

45% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Mario E. Lacouture is affiliated with Memorial Sloan Kettering Cancer Center in the United States and specializes in the field of medicine, with a focused expertise in oncology and dermatology. Their research portfolio comprises 435 publications in medicine, including 140 specifically in oncology and 85 in dermatology. Additional subfields of their work include molecular biology, epidemiology, and immunology.

The main topics addressed in Lacouture's research include chemotherapy-related skin toxicity, colorectal cancer treatments and studies, and cancer immunotherapy and biomarkers. Other notable research areas are nonmelanoma skin cancer studies, hair growth and disorders, cancer treatment and pharmacology, and autoimmune bullous skin diseases.

Frequent coauthors in Lacouture's publications include Alina Markova, Stephen W. Dusza, Lukas Kraehenbuehl, Donald Y.M. Leung, and Veronica Rotemberg. These collaborations contribute to a broad and interdisciplinary approach within their research scope.

Mario E. Lacouture has published extensively in multiple research venues. Some venues with the highest number of publications include the Journal of the American Academy of Dermatology with 30 publications, the Journal of Clinical Oncology with 29, Diabetes with 9, Circulation with 8, and Annals of Oncology with 7.

Recent notable papers authored or coauthored by Lacouture include:

  • Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines, 2020, Annals of Oncology
  • Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events, 2021, Journal for ImmunoTherapy of Cancer
  • Immune checkpoint inhibitor-related dermatologic adverse events, 2020, Journal of the American Academy of Dermatology
  • Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features, 2020, Journal of the American Academy of Dermatology
  • Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors, 2020, Nature Cancer

Best Publications

  • Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

    I. Puzanov;A. Diab;K. Abdallah;C. O. Bingham

  • Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies

    J. Naidoo;D. B. Page;B. T. Li;L. C. Connell

  • Mechanisms of cutaneous toxicities to EGFR inhibitors.

    Mario E. Lacouture

  • Management of Immunotherapy-Related Toxicities, Version 1.2019.

    John A. Thompson;Bryan J. Schneider;Julie Brahmer;Stephanie Andrews

  • Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a Phase II, Open-Label, Randomized Trial Evaluating the Impact of a Pre-Emptive Skin Treatment Regimen on Skin Toxicities and Quality of Life in Patients With Metastatic Colorectal Cancer

    Mario E. Lacouture;Edith P. Mitchell;Bilal Piperdi;Madhavan V. Pillai

  • Society for immunotherapy of cancer (sitc) clinical practice guideline on immune checkpoint inhibitor-related adverse events

    Julie R. Brahmer;Hamzah Abu-Sbeih;Paolo Antonio Ascierto;Jill Brufsky

  • Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities

    Mario E. Lacouture;Milan J. Anadkat;René-Jean Bensadoun;Jane Bryce

  • Epidermal Growth Factor Receptor Inhibitor–Associated Cutaneous Toxicities: An Evolving Paradigm in Clinical Management

    Thomas J. Lynch;Ed S. Kim;Beth Eaby;Jody Garey

  • Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms

    Eli L. Diamond;Benjamin H. Durham;Julien Haroche;Zhan Yao

  • Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.

    Mario E. Lacouture;Shenhong Wu;Caroline Robert;Michael B. Atkins

  • Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor.

    V.R. Belum;B. Benhuri;B. Benhuri;M.A. Postow;M.A. Postow;M.D. Hellmann;M.D. Hellmann

  • Grading dermatologic adverse events of cancer treatments: The Common Terminology Criteria for Adverse Events Version 4.0

    Alice P. Chen;Ann Setser;Milan J. Anadkat;Jonathan Cotliar

  • Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study

    Eli L. Diamond;Eli L. Diamond;Vivek Subbiah;A. Craig Lockhart;Jean Yves Blay

  • Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia

    E. Tiacci;J. H. Park;L. De Carolis;S. S. Chung

  • First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study

    Ryan J. Sullivan;Jeffrey R. Infante;Filip Janku;Deborah Jean Lee Wong

  • Immune checkpoint inhibitor–related dermatologic adverse events

    Amaris N. Geisler;Gregory S. Phillips;Dulce M. Barrios;Jennifer Wu

  • Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails

    Mario Lacouture;Vincent Sibaud

  • Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib

    M. E. Lacouture;L. M. Reilly;P. Gerami;J. Guitart

  • Efficacy of MEK inhibition in patients with histiocytic neoplasms

    Eli L. Diamond;Benjamin H. Durham;Gary A. Ulaner;Esther Drill

  • Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC.

    Fernando Costa Santini;Hira Rizvi;Andrew J. Plodkowski;Andy Ni

Frequent Co-Authors

Klaus J. Busam
Klaus J. Busam Memorial Sloan Kettering Cancer Center
David M. Hyman
David M. Hyman Memorial Sloan Kettering Cancer Center
Michael A. Postow
Michael A. Postow Memorial Sloan Kettering Cancer Center
Omar Abdel-Wahab
Omar Abdel-Wahab Memorial Sloan Kettering Cancer Center
Jedd D. Wolchok
Jedd D. Wolchok Cornell University
Alfred W. Rademaker
Alfred W. Rademaker Northwestern University
Neal Rosen
Neal Rosen Memorial Sloan Kettering Cancer Center
Paul B. Chapman
Paul B. Chapman Memorial Sloan Kettering Cancer Center
Michael F. Berger
Michael F. Berger Memorial Sloan Kettering Cancer Center
Matthew D. Hellmann
Matthew D. Hellmann Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medicine in the USA opens doors to diverse online degree options and healthcare career paths. Many students look for specialized programs that fit their aspirations and busy schedules.

For those interested in mental health, psych np programs provide advanced training for nurse practitioners focused on psychiatric care, typically offered in flexible online formats.

If affordability matters, you’ll find the cheapest online health science degree options help start a healthcare career without heavy debt. For leadership roles, the cheapest online master degree in healthcare administration equips graduates to manage teams or facilities.

Registered nurses aiming for the highest qualifications may consider the cheapest online bsn to dnp programs. These programs lead to a Doctor of Nursing Practice, unlocking clinical and executive positions.

Online programs offer flexibility and cost savings, making it easier to pursue healthcare and medical careers suited to your interests and financial goals.

Best Scientists Citing Mario E. Lacouture

Trending Scientists

Recently Published Articles